| P2093 | author name string | George V Papatheodoridis | |
| | George N Dalekos | |
| | John Koskinas | |
| P2860 | cites work | Early normalisation of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients | Q84242690 |
| | The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes | Q84348272 |
| | Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis | Q84538098 |
| | British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis | Q84561367 |
| | Clinicopathological features of severe and fulminant forms of autoimmune hepatitis | Q84990082 |
| | EASL Clinical Practice Guidelines: Autoimmune hepatitis | Q86075911 |
| | Pregnancy and childbirth in women with autoimmune hepatitis is safe, even in compensated cirrhosis | Q86846872 |
| | Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents | Q87018180 |
| | Long-term outcome in PSC/AIH "overlap syndrome": does immunosuppression also treat the PSC component? | Q87543432 |
| | Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis | Q87549139 |
| | Nonalcoholic Fatty Liver Disease in Patients with Autoimmune Hepatitis: Further Reason for Teeth GNASHing? | Q88015400 |
| | Use of sirolimus in the treatment of refractory autoimmune hepatitis | Q88185818 |
| | EASL Recommendations on Treatment of Hepatitis C 2018 | Q88344766 |
| | Methotrexate Therapy for Autoimmune Hepatitis | Q88528088 |
| | Editorial: autoimmune hepatitis - identifying options for treatment. Authors' reply | Q89353542 |
| | Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis | Q89389161 |
| | Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis | Q91688408 |
| | Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system | Q94054254 |
| | Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement | Q95826238 |
| | Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease | Q24804699 |
| | The Human SepSecS-tRNASec Complex Reveals the Mechanism of Selenocysteine Formation | Q27656503 |
| | Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics | Q28087726 |
| | Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis | Q28115454 |
| | Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis | Q28289028 |
| | Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? | Q30229501 |
| | Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. | Q33563872 |
| | Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature | Q33647736 |
| | International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis | Q33784003 |
| | Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents | Q33861220 |
| | Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy | Q33898237 |
| | A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome | Q33916375 |
| | Diagnosis and management of autoimmune hepatitis | Q34118165 |
| | Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center | Q34170088 |
| | Autoimmune hepatitis triggered by nitrofurantoin: a case series | Q34199672 |
| | Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy | Q34286525 |
| | Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. | Q34299536 |
| | Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study | Q34325009 |
| | Review article: autoimmune hepatitis -- current management and challenges. | Q34369116 |
| | Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis | Q34494662 |
| | Autoantibodies directed against the UDP-glucuronosyltransferases in human autoimmune hepatitis | Q34545376 |
| | Hepatocellular carcinoma in patients with autoimmune hepatitis. | Q34604173 |
| | EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | Q34676840 |
| | Autoimmune hepatitis and overlap syndromes | Q34746158 |
| | Autoimmune acute liver failure: proposed clinical and histological criteria | Q34822608 |
| | The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. | Q35341829 |
| | Liraglutide-induced autoimmune hepatitis | Q35580550 |
| | De novo autoimmune hepatitis after liver transplantation | Q35606671 |
| | Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. | Q45773333 |
| | Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. | Q45910292 |
| | Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. | Q46009237 |
| | Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. | Q46034647 |
| | Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission | Q46043766 |
| | Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells | Q46057972 |
| | Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. | Q46197799 |
| | Mycophenolate mofetil for autoimmune hepatitis: a single practice experience | Q46198163 |
| | Mycophenolate mofetil as second line therapy in autoimmune hepatitis? | Q46317682 |
| | Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome | Q46391510 |
| | Mycophenolate mofetil promotes down-regulation of expanded B cells and production of TNF-alpha in an experimental murine model of colitis | Q46454872 |
| | Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis | Q46470337 |
| | Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis | Q46502311 |
| | Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome | Q46572197 |
| | Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus | Q46584599 |
| | The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. | Q46666374 |
| | Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease | Q46689681 |
| | Budesonide in previously untreated autoimmune hepatitis. | Q46702694 |
| | Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis | Q46847236 |
| | Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome | Q46852534 |
| | Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis | Q47406857 |
| | Autoimmune hepatitis in the setting of human immunodeficiency virus infection: A case series | Q47550106 |
| | Rapidity of treatment response and outcome in type 1 autoimmune hepatitis | Q47787859 |
| | EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure | Q47810347 |
| | Pregnancy in autoimmune hepatitis: outcome and risk factors | Q47858204 |
| | Autoimmune hepatitis in Italy: the Bologna experience | Q47939731 |
| | Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors | Q48631265 |
| | Natural History and Treatment Outcomes of Severe Autoimmune Hepatitis | Q48685675 |
| | Budesonide in Autoimmune Hepatitis: The Right Drug at the Right Time for the Right Patient | Q50058130 |
| | Serology in autoimmune hepatitis: A clinical-practice approach | Q50065522 |
| | Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. | Q50099174 |
| | Is there a role for viruses in triggering autoimmune hepatitis? | Q50101314 |
| | Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. | Q50513527 |
| | Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. | Q51100139 |
| | Autoimmune hepatitis in southern Israel: a 15-year multicenter study. | Q51218632 |
| | Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation. | Q51331002 |
| | Population-based epidemiology study of autoimmune hepatitis: a disease of older women? | Q51539848 |
| | Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. | Q51596178 |
| | Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. | Q51757425 |
| | Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey. | Q52687643 |
| | Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study. | Q52780455 |
| | Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis. | Q53150319 |
| | Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. | Q53160616 |
| | Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? | Q53175499 |
| | Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. | Q53191503 |
| | Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. | Q53191508 |
| | Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. | Q53240102 |
| | Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. | Q53271951 |
| | Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. | Q53458855 |
| | Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand | Q54248274 |
| | Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model | Q39961596 |
| | Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis | Q42108248 |
| | Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome | Q42246103 |
| | Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis | Q42285314 |
| | Autoimmune Hepatitis or Wilson's Disease, a Clinical Dilemma | Q42536152 |
| | Acute autoimmune hepatitis: many open questions | Q42670620 |
| | Optimizing management in autoimmune hepatitis with liver failure at initial presentation | Q42723758 |
| | Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis | Q42834116 |
| | Treatment response in patients with autoimmune hepatitis | Q42918487 |
| | Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis | Q42989153 |
| | Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. | Q43050091 |
| | Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. | Q43244249 |
| | Laboratory-based scoring system for prediction of hepatic inflammatory activity in patients with autoimmune hepatitis. | Q43434701 |
| | Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). | Q43439577 |
| | Recurrent autoimmune hepatitis after orthotopic liver transplantation | Q43575678 |
| | Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. | Q43711731 |
| | Concurrent autoimmune diseases in patients with autoimmune hepatitis | Q43717163 |
| | Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis | Q43758596 |
| | Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome | Q43769161 |
| | Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece | Q43848712 |
| | Prognosis of autoimmune hepatitis showing acute presentation | Q43886957 |
| | Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis | Q43933947 |
| | Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study | Q44002132 |
| | Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis. | Q44191674 |
| | Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare | Q44225005 |
| | Simplified criteria for the diagnosis of autoimmune hepatitis | Q44425899 |
| | Corticosteroids do not reverse the inhibitory effect of cyclosporine on regulatory T-cell activity in contrast to mycophenolate mofetil | Q44708185 |
| | Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. | Q44728174 |
| | Use of TNFα antagonists in refractory AIH: revealing the unforeseen | Q44930293 |
| | Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis | Q45002713 |
| | Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy | Q45016057 |
| | Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding | Q45116620 |
| | Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact? | Q45353176 |
| | Occult hepatitis B virus infection in patients with autoimmune liver diseases | Q45392120 |
| | The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders | Q35914823 |
| | Mechanisms of action of mycophenolate mofetil | Q36085841 |
| | Molecular diagnostic testing for primary biliary cholangitis | Q36086498 |
| | Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop | Q36740188 |
| | Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States | Q36844723 |
| | Anti-alpha-actinin antibodies: a new marker of lupus nephritis | Q36888138 |
| | Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? | Q36899264 |
| | Steroid use in acute liver failure | Q36939687 |
| | Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy | Q37075975 |
| | A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis | Q37202406 |
| | Clinical features in different age groups of patients with autoimmune hepatitis | Q37387438 |
| | Autoimmune hepatitis in patients with human immunodeficiency virus (HIV): Case reports of a rare, but important diagnosis with therapeutic implications | Q37656269 |
| | Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials | Q37733093 |
| | Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue | Q37808546 |
| | Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity | Q37829507 |
| | Acute presentation of autoimmune hepatitis: Does it exist? A published work review | Q37877293 |
| | Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. | Q37946105 |
| | Outcomes of pregnancy in women with autoimmune hepatitis. | Q37977274 |
| | Autoimmune hepatitis in diverse ethnic populations and geographical regions | Q38103631 |
| | Autoimmune hepatitis: Contrasts and comparisons in children and adults - a comprehensive review | Q38137502 |
| | Autoimmune liver disease, autoimmunity and liver transplantation. | Q38148392 |
| | Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly | Q38164847 |
| | Current and prospective pharmacotherapy for autoimmune hepatitis | Q38222882 |
| | Obesity in autoimmune diseases: not a passive bystander | Q38237025 |
| | Theory to reality: the role of the transition nurse coordinator | Q38247408 |
| | EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection | Q38692559 |
| | Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. | Q38731224 |
| | Expert clinical management of autoimmune hepatitis in the real world | Q38779430 |
| | Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis | Q38996810 |
| | Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. | Q39051463 |
| | Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. | Q39183281 |
| | Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. | Q39518046 |
| | Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease. | Q39709297 |
| | A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis | Q39909124 |
| | Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune Hepatitis. | Q54572192 |
| | EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 |
| | Postinfantile Giant Cell Hepatitis with Features of Acute Severe Autoimmune Hepatitis Probably Triggered by Diclofenac in a Patient with Primary Myelofibrosis. | Q55096623 |
| | AASLD guidelines for the treatment of hepatocellular carcinoma | Q56172239 |
| | Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study | Q56374625 |
| | Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease | Q57062009 |
| | Family occurrence of autoimmune hepatitis: A Danish nationwide registry-based cohort study | Q58301008 |
| | Autoimmune hepatitis | Q59349440 |
| | De Novo Autoimmune Hepatitis Following Liver Transplantation | Q59359557 |
| | EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis | Q59384401 |
| | Patients With Autoimmune Hepatitis Who Have Antimitochondrial Antibodies Need Long-term Follow-up to Detect Late Development of Primary Biliary Cirrhosis | Q59384441 |
| | Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: A nationwide study | Q59490154 |
| | Response to steroids in de novo autoimmune hepatitis after liver transplantation | Q62616297 |
| | Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent | Q70280999 |
| | Meeting report: International Autoimmune Hepatitis Group | Q70496892 |
| | Autoimmune hepatitis | Q70868063 |
| | Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis | Q71373108 |
| | Azathioprine for Long-Term Maintenance of Remission in Autoimmune Hepatitis | Q72039839 |
| | Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis | Q73130778 |
| | Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system | Q73144379 |
| | [Liver, blood proteins and nutritive protein] | Q73461749 |
| | Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study | Q73568156 |
| | Duration of immunosuppressive therapy in autoimmune hepatitis | Q73700106 |
| | Lupoid hepatitis | Q74334969 |
| | Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy | Q74424827 |
| | Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview | Q74529379 |
| | Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy | Q77058192 |
| | Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment | Q77221647 |
| | Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1 | Q79138718 |
| | How common are connective tissue disorders in patients with autoimmune hepatitis? | Q79717038 |
| | Development of antimitochondrial antibodies in patients with autoimmune hepatitis: art of facts or an artifact? | Q79763306 |
| | Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis | Q79788278 |
| | Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse | Q79825440 |
| | Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis | Q80022983 |
| | Consequences of treatment withdrawal in type 1 autoimmune hepatitis | Q80085817 |
| | Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre | Q80087406 |
| | Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis | Q80119655 |
| | Anti-alpha-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis | Q80497773 |
| | Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease | Q80720176 |
| | Celiac disease-related autoantibodies in end-stage autoimmune liver diseases: what is the message? | Q80867366 |
| | Safety issues in the management of autoimmune hepatitis | Q81230534 |
| | Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1 | Q82325135 |
| | Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients | Q82344181 |
| | Recognizing autoimmune hepatitis: scores help, but no more | Q82536747 |
| | Features and consequences of untreated type 1 autoimmune hepatitis | Q82661355 |
| | Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment | Q82824269 |
| | Autoimmune hepatitis | Q82936688 |
| | Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy, and outcomes | Q83578896 |
| | Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients | Q83744507 |
| | Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis | Q83989361 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gastroenterology | Q120569 |
| | autoimmune hepatitis | Q786844 |
| P304 | page(s) | 1-23 | |
| P1433 | published in | Annals of Gastroenterology | Q15758811 |
| P1476 | title | Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis | |
| P478 | volume | 32 | |